drugset / Trial / NCT01549041

Once-Daily Asenapine for Schizophrenia

NCT01549041

Phase 4 Completed 30 enrolled Duke University Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators propose to explore: 1. the acceptance by patients of once versus twice daily dosing with asenapine, 2. the acceptance by staff of once versus twice daily dosing with asenapine, and 3. the changes in psychopathology associated with these two dosing strategies, in 30 patients with schizophrenia or schizoaffective disorder. The investigators hypothesize that patient and staff acceptance will be better with once daily dosing and that improvements in psychopathology will be similar across once daily and twice daily dosing

Timeline

Start
2012-04
Primary completion
2013-04
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Asenapine Other / unclassified 5 mg
Subject Asenapine Other / unclassified 10 mg

Indications